Navigation Links
NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil®
Date:6/5/2011

CHICAGO, June 5, 2011 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced positive results from a subpopulation of patients in a Phase 2 clinical study evaluating single-agent NKTR-102 in women with platinum-resistant/refractory ovarian cancer.  A total of 33 women in the study with prior Doxil® (pegylated liposomal doxorubicin or PLD) treatment were evaluable for response rate using either RECIST 1.0 criteria (response by tumor imaging) or Gynecologic Cancer InterGroup (GCIG) criteria, which is a combination of RECIST and/or ovarian cancer biomarker (CA-125) criteria.(1)  Confirmed and unconfirmed objective response rates using RECIST were 25 percent (4/16) and 29 percent (4/14) for the q14d and q21d dose schedules, respectively.  Confirmed objective response rates using RECIST were 19 percent (3/16) and 21 percent (3/14) for each dose schedule, respectively.  GCIG (confirmed and unconfirmed) response rates were 50 percent (8/16) in the once every 14 days (q14d) dose schedule and 35 percent (6/17) for the once every 21 days (q21d) dose schedule.  Confirmed objective GCIG response rates were 38 percent (6/16) and 35 percent (6/17) in the q14d and q21d dose schedules, respectively.

Median progression-free survival for all 33 patients in the subpopulation previously treated with PLD was 5.4 months and median overall survival was 13.9 months.  The median duration of confirmed response was 4.2 months in the q14d schedule and 4.4 months in the q21d schedule.

"NKTR-102 exhibits an exceptionally high response rate and long median survival compared to what would be expected in this group of heavily pre-treated women with platinum-resistant and refractory ovarian cancer," said Dr. Agustin Garcia, Associate Professor of Clinical Medicine at USC Norris Comprehensive Center.  "Women whose cancer has progressed following trea
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. NKTR-102 Demonstrates Sustained Clinical Benefit in 46% of Patients with Metastatic Breast Cancer in Data Presented at 2011 American Society of Clinical Oncology Annual Meeting
2. Nektar Announces New Phase 2 Data for NKTR-102 to Be Presented at 2011 ASCO Annual Meeting
3. FDA Grants Orphan Drug Designation for Nektars Investigational Drug, NKTR-102, for Treatment of Women with Ovarian Cancer
4. NKTR-102 Demonstrates Significant Efficacy as Single-Agent in Second- or Third-Line Treatment in Metastatic Breast Cancer Patients
5. NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress
6. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
7. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
8. Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings
9. Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting
10. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
11. NKTR-102 (PEG-Irinotecan) Demonstrates Significant Tumor Growth Inhibition In Multiple Preclinical Tumor Models
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 29, 2014 Pomerantz LLP has filed a ... "Company") (NASDAQ: EDAP ) and certain of ... District Court, Southern District of New York ... of a class consisting of all persons or entities ... July 30, 2014, inclusive (the "Class Period"). This class action ...
(Date:8/29/2014)... Calif. , Aug. 29, 2014 Medina ... as CEO and member of the Board of Directors ... of medical device development and commercialization experience, including over ... Mr. Engelson previously served as a Partner of the ... President and CEO of two Foundry start-ups. Mr. Engelson ...
(Date:8/29/2014)... , Aug. 29, 2014 Research and ... "China Orthopedic Instrument Industry Report, 2014-2017" report to ... population and rising proportion of reimbursement for medical expenses, ... released, with its scale presenting a CAGR of 19.2% ... are three product segments of orthopedic instruments in ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP 3Medina Medical Announces Erik T. Engelson Joins as Chief Executive Officer 2China Orthopedic Instrument Industry Report, 2014-2017 2
... , Medicare Beneficiaries in Eight Montana Counties May Be ... No Access to a Medicare Approved Supplier , WASHINGTON, ... equipment suppliers on October 30th, a Center for Medicare and ... a Medicare beneficiary may experience supplier access issues in obtaining ...
... Hospital in the Chicago suburb of Park Ridge has chosen ... for RapidArc(TM), and, in doing so, becomes the 100th clinical ... system, cancer care physicists and physicians at Advocate Lutheran General ... therapy treatment. Key to this is the capability to ...
Cached Medicine Technology:CMS Admits New Surety Bond and Accreditation Requirement for Home Medical Equipment Suppliers Creating Patient Access Issues 2CMS Admits New Surety Bond and Accreditation Requirement for Home Medical Equipment Suppliers Creating Patient Access Issues 3ScandiDos Sells 100th Delta4(R) PT Unit as Adoption of Rotational Therapy Cancer Treatment Increases 2ScandiDos Sells 100th Delta4(R) PT Unit as Adoption of Rotational Therapy Cancer Treatment Increases 3
(Date:9/1/2014)... 02, 2014 Renal cell carcinoma (RCC) is ... of the proximal convoluted tubule, a part of the very ... the blood to the urine. The condition is asymptomatic in ... are often in the advanced stages of the disease by ... often include blood in the urine, flank pain, a mass ...
(Date:9/1/2014)... Liver is the largest organ inside the human ... body in barring itself from poisons, helps in digestion of ... plays many important functions such as protein production, blood clotting ... illnesses can affect the liver, an organ the size of ... right side of the abdomen, reducing its capabilities to perform ...
(Date:9/1/2014)... "Women struggle with weight gain typically associated ... as early as 15, if not earlier. Women ... and downs of hormone related weight gain. The ... seems to rage against the hidden and ever-present hormones ... 40's begin to face menopause and related changes, these ...
(Date:9/1/2014)... Permanent atrial fibrillation (AF) doubles the risk of stroke ... than 6 000 patients presented at ESC Congress today ... that a simple clinical assessment of the type of ... , Ischaemic stroke is the second cause of death ... and many more disabled patients each year. Annual direct ...
(Date:9/1/2014)... New York (PRWEB) September 01, 2014 ... store, retrieve, organize and analyze biological and genetic ... of the activity of developing software tools to ... not to be confused with biological computation. While ... better understanding of biology can its related concepts, ...
Breaking Medicine News(10 mins):Health News:Renal Cell Carcinoma Market Analysis & Epidemiology Forecast to 2023 Says a New Report Available at MarketOptimizer.org 2Health News:Renal Cell Carcinoma Market Analysis & Epidemiology Forecast to 2023 Says a New Report Available at MarketOptimizer.org 3Health News:Renal Cell Carcinoma Market Analysis & Epidemiology Forecast to 2023 Says a New Report Available at MarketOptimizer.org 4Health News:Global Liver Diseases and Therapies Market- The Key Basics by Transparency Market Research 2Health News:Global Liver Diseases and Therapies Market- The Key Basics by Transparency Market Research 3Health News:Female Hormonal Imbalances - Can’t Seem to Shed Those Extra Pounds? Discussion with Medical Expert Dr. Clairborne on Dr. Carol Francis Talk Radio Today 2Health News:Female Hormonal Imbalances - Can’t Seem to Shed Those Extra Pounds? Discussion with Medical Expert Dr. Clairborne on Dr. Carol Francis Talk Radio Today 3Health News:Permanent AF doubles risk of stroke compared to paroxysmal AF 2Health News:Bioinformatics Market: A fusion of Computers and Biological Data 2Health News:Bioinformatics Market: A fusion of Computers and Biological Data 3Health News:Bioinformatics Market: A fusion of Computers and Biological Data 4
... throat area helps people who cannot swallow because of paralysis. ... of various of the cranial nerves. One of these, the ... the digestive tract// - that is, above the esophagus, but ... food down to the lungs, and swallowing difficulties may occur. ...
... therapy may be an effective treatment for depression in ... psychiatry at the Yale School of Medicine in New ... non-toxic antidepressant light therapy in pregnancy is a clinically ... to see whether exposure to bright light, a technique ...
... compressing DNA which could make gene therapy powerful. The advance ... may allow the modified genes to slip right into the ... for building an entire human.// ,This means that the ... ways to smuggle or slip their modified DNA strands into ...
... A new trial shows that the symptoms of Lyme ... bacterium that lives in tiny ticks, sometimes produces very ... is standard, researchers in Texas feel that this treatment ... ,They studied 40 Lyme patients, some of ...
... According to a new research, conducted by the ... gum has a positive effect on thinking, memory and ... clear and specifically we found that chewing gum// targeted ... Unit said. "People recalled more words and performed better ...
... of surgery. Lens as thick as two strand of ... coronary bypass surgery. The main problem with bypass surgery ... and requiring further treatment.// If changes in blood flow ... stage, it's possible that such complications could be averted. ...
Cached Medicine News:
... chairs with concave seats and standard-sized ... options like seats, backrests, armrests, and ... are recommended for the following environments: ... control, health care and office. • ...
... Basic ergonomic chairs with concave ... support • Select options like seats, ... • BTC/1Q chairs are recommended for ... clean room, static control, health care ...
... with concave seats and standard-sized backrests ... like seats, backrests, armrests, and casters ... recommended for the following environments: industry, ... health care and office. • With ...
... chairs with concave seats and standard-sized ... options like seats, backrests, armrests, and ... are recommended for the following environments: ... control, health care and office. • ...
Medicine Products: